In this Healio Video Perspective from the Retina World Congress, Ashish Sharma, MBBS, MS, gives an update on aflibercept ...

Data showcased in session titled “Spotlight on Drug Delivery” at the Ophthalmology Innovation Source (OIS) Retina 8th Annual Innovation Summit -VLTR-559, a long-acting anti-VEGF therapy, could reduce ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...

EyePoint Pharmaceuticals has concluded subject enrolment in the pivotal Phase III programme assessing Duravyu, aimed at ...

On July 17, 2025, Harrow, Inc. (“Harrow”), announced an agreement with Samsung Bioepis Co. Ltd. (“Samsung Bioepis”) to acquire the U.S.

ANI Pharmaceuticals (ANIP) stock drops as its Iluvien implant fails in a clinical trial versus Eylea marketed by Regeneron ...

In ANI's New Day trial, patients were randomized to an induction phase to receive either a single Iluvien injection or a series of five monthly injections of aflibercept, followed by supplemental ...

In this Healio Video Perspective from the ARVO meeting, Michael Javaheri, MD, overviews real-world data on Eylea HD in ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal community – – ...